Sodium Nitrite to Treat Arterial Aging

NCT ID: NCT02022670

Last Updated: 2015-07-15

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

33 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-10-31

Study Completion Date

2013-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The proposed research will determine the effectiveness of nitrite, a naturally occurring compound in the body, for improving the health and function of arteries in middle-aged and older adults. The study also will provide insight into how sodium nitrite therapy improves artery health by determining the physiological mechanisms (biological reasons) involved. Overall, the proposed research will provide important new scientific evidence on the effectiveness of sodium nitrite for decreasing the risk of developing cardiovascular diseases with aging.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The improvement in blood vessel function and stiffness will be determined over a 10 week period. Subjects will be randomly assigned to either placebo (0 mg/day), low dose (80 mg/day) or high dose (160 mg/day) sodium nitrite. Main outcome measures will be performed at baseline and week 10.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vascular Aging

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

inert oral capsules (0 mg sodium nitrite morning; 0 mg sodium nitrite in evening) for 10 weeks

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Sugar pill manufactured to mimic sodium nitrite capsules

Sodium Nitrite 80 mg/d

80 mg/day (40 mg in morning; 40 mg in evening) oral capsules for 10 weeks

Group Type EXPERIMENTAL

Sodium Nitrite

Intervention Type DRUG

80 mg/d or 160 mg/d

Sodium Nitrite 160 mg/d

160 mg/day (80 mg in morning; 80 mg in evening) oral capsules for 10 weeks

Group Type EXPERIMENTAL

Sodium Nitrite

Intervention Type DRUG

80 mg/d or 160 mg/d

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Placebo

Sugar pill manufactured to mimic sodium nitrite capsules

Intervention Type DRUG

Sodium Nitrite

80 mg/d or 160 mg/d

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

TV1001

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 50-79 years of age
* Ability to provide informed consent
* Score greater than 22 on the mini mental state exam
* Blood pressure greater than 100/60 mmHg for past 3 months

Exclusion Criteria

* Are taking any of the following medications/drugs: hormone replacement therapy, anti-hypertensives, nitrates, nervous system depressants, allopurinol, phosphodiesterase-5 inhibitors, blood thinners
* Are currently sick/have chronic clinical diseases such as kidney disease, diabetes, or unstable cardiovascular disease
* Are hypersensitive to nitrates or nitrites
* Have glucose-6-phosphate dehydrogenase deficiency
* Have blood methemoglobin greater than 2%
* Have a BMI greater than 40 kg/m\^2
* Have a baseline FMD of greater than 6%
* Have not been post-menopausal for at least 1 year
* Perform regular vigorous aerobic/endurance exercise
Minimum Eligible Age

50 Years

Maximum Eligible Age

79 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

TheraVasc Inc.

INDUSTRY

Sponsor Role collaborator

University of Colorado, Boulder

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Douglas R Seals, Ph.D.

Role: PRINCIPAL_INVESTIGATOR

University of Colorado, Boulder

Allison E DeVan, Ph.D.

Role: STUDY_DIRECTOR

University of Colorado, Boulder

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Clinical Translational Research Center

Boulder, Colorado, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Related Links

Access external resources that provide additional context or updates about the study.

http://www.colorado.edu/intphys/research/cardiovascular.html

Integrative Physiology of Aging Laboratory Website

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

R21HL107105

Identifier Type: NIH

Identifier Source: org_study_id

View Link

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Dietary Salt Intake and Vascular Function
NCT00590512 COMPLETED EARLY_PHASE1
Nitrate Supplementation; Source
NCT02271633 COMPLETED PHASE4